V 
PATIENT EVALUATION 
Parameters to be Measured 
Pre During Therapy - Week . 
Study ^ D3 ^ ^ D20 7 ._8 
Physical exam X 
History X 
Performance Status X 
Assess for Tumor Effect^ X 
Chemistry Survey^ X 
Vital Signs X 
Weight X 
CBC, Diff, Platelet X 
PT , PTT X 
FEVl , ABCs X 
EKG X 
CXR X 
Cardiac Stress Test X 
U/A and Culture X 
HbgAg, HTLV III X 
Brain CT or MRI X 
Assess for adverse 
events status 
PCR on PBL to detect 
TNF gene X 
Tumor biopsy (if feasible) X 
Western blot 
(4070A envelope) X 
Serum assay for TNF X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X X 
X X 
X X 
X 
XXX 
X X 
X X 
X X 
X X X X X 
X 
X 
X 
^To include assessment of all sites of disease. 
^Includes total bilirubin, SCOT, LDH, Alkaline Phosphatase, Creatinine, Bun, CPK 
1. Pretreatment (see Table, page 17). 
a. Complete physical examination noting in detail the exact size 
and location of any lesions that exist. 
b. Complete chemistry survey including electrolytes, liver function 
tests, calcium, magnesium, creatinine, BUN, CPK. 
c. CBC diferential count, PT, PTT, platelet count 
d. Urine analysis and culture 
e. Hepatitis screen 
f. HIV titer 
[276] 
Recombinant DNA Research, Volume 14 
